Gilead Discontinues Development of Cicletanine

Dow Jones reported yesterday that Gilead Sciences have dropped the diuretic cicletanine after it failed to meet targets in a mid-stage clinical trial analysing the drug’s potential in high blood pressure. The Phase II, randomised, double-blind, placebo-controlled, multicenter, dose- ranging study was evaluating the efficacy, safety and tolerability of cicletanine in comparison to a placebo

Continue Reading

ABPI Publish Updated Phase I Clinical Trial Guidelines

The Association of the British Pharmaceutical Industry (ABPI) amended their guidelines on Phase I trials on Tuesday to echo alterations in the UK’s regulatory framework since the previous guidelines were issued in 2007. Since 2007, the association notes that “a considerable amount of what previously constituted guidance has now become requirement.” The updated guidelines are

Continue Reading

Bayer To Submit Regorafenib After Positive Survival Statistics

Bayer has provided more information about their recently-halted late-stage trial of their colorectal cancer drug, regorafenib, which shows that the drug improved overall survival by 29%, meeting its primary endpoint. In October, the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial, which contained 760 patients with metastatic

Continue Reading